Clinical and economic challenges facing pharmacogeno

Pharmacogenomics Journal
13, 378-388
DOI: 10.1038/tpj.2011.63

Citation Report

#	Article	IF	Citations
1	Best practices for companion diagnostic and therapeutic development: translating between the stakeholders. New Biotechnology, 2012, 29, 689-694.	2.4	12
2	Complexities ofCYP2D6gene analysis and interpretation. International Review of Psychiatry, 2013, 25, 534-553.	1.4	188
3	Scientific Challenges and Implementation Barriers to Translation of Pharmacogenomics in Clinical Practice. ISRN Pharmacology, 2013, 2013, 1-17.	1.6	50
4	Translating Pharmacogenomic Research to Therapeutic Potentials. , 2013, , 45-61.		1
5	Automation of diagnostic genetic testing: Mutation detection by cyclic minisequencing. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 44-52.	0.6	2
6	Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 210-214.	0.7	6
7	Stakeholder Views on Pharmacogenomic Testing. Pharmacotherapy, 2014, 34, 151-165.	1.2	43
8	Emerging Roles for Pharmacists in Clinical Implementation of Pharmacogenomics. Pharmacotherapy, 2014, 34, 1102-1112.	1.2	105
9	Personalized Therapeutics and Companion Diagnostics: A New Paradigm in Testing and Treatment. Clinical Chemistry, 2014, 60, 795-796.	1.5	2
10	Useless Until Proven Effective: The Clinical Utility of Preemptive Pharmacogenetic Testing. Clinical Pharmacology and Therapeutics, 2014, 96, 652-654.	2.3	37
11	Array-based sensing using nanoparticles: an alternative approach for cancer diagnostics. Nanomedicine, 2014, 9, 1487-1498.	1.7	34
12	Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. Genetical Research, 2015, 97, e13.	0.3	48
13	International differences in companion diagnostic approvals: how are we able to manage the differences?. Expert Review of Molecular Diagnostics, 2015, 15, 157-159.	1.5	11
14	An evaluation of regulatory and commercial barriers to stratified medicine development and adoption. Pharmacogenomics Journal, 2015, 15, 6-12.	0.9	15
15	Expansion of pharmacogenomics into the community pharmacy: billing considerations. Pharmacogenomics, 2015, 16, 175-180.	0.6	15
16	The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics. Drug Discovery Today, 2015, 20, 1439-1450.	3.2	13
17	Biopharmaceutical factory of the future. Pharmaceutical Bioprocessing, 2015, 3, 293-304.	0.8	6
18	A perspective analysis: companion diagnostics: an evolving paradigm in 21st century healthcare. Personalized Medicine, 2015, 12, 389-402.	0.8	6

#	Article	IF	Citations
19	Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. Annual Review of Pharmacology and Toxicology, 2015, 55, 89-106.	4.2	442
20	Early Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine. OMICS A Journal of Integrative Biology, 2016, 20, 30-35.	1.0	7
21	Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. Mayo Clinic Proceedings, 2016, 91, 897-907.	1.4	62
22	Requirements for comprehensive pharmacogenetic genotyping platforms. Pharmacogenomics, 2016, 17, 917-924.	0.6	40
23	Overcoming regulatory challenges in the development of companion diagnostics for monitoring and safety. Personalized Medicine, 2016, 13, 155-167.	0.8	1
24	A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers. Applied Health Economics and Health Policy, 2016, 14, 51-65.	1.0	28
25	A review of international coverage and pricing strategies for personalized medicine and orphan drugs. Health Policy, 2017, 121, 1240-1248.	1.4	23
26	Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research. Genetic Testing and Molecular Biomarkers, 2017, 21, 705-716.	0.3	11
28	TBC update: attitudes of oncology nurses concerning pharmacogenomics. Personalized Medicine, 2017, 14, 515-520.	0.8	2
29	Access to Guideline-Recommended Pharmacogenomic Tests for Cancer Treatments: Experience of Providers and Patients. Journal of Personalized Medicine, 2017, 7, 17.	1.1	7
30	Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Innerâ€€City Population. Pharmacotherapy, 2018, 38, 205-216.	1.2	21
31	Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 500-506.	0.7	6
32	Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants. Oncotarget, 2018, 9, 29238-29258.	0.8	26
33	Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer. Journal of Personalized Medicine, 2018, 8, 19.	1.1	30
34	Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e116-e136.	2.5	49
35	Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan. Drug Metabolism and Pharmacokinetics, 2018, 33, 243-249.	1.1	3
36	Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics, 2018, 19, 847-860.	0.6	53
37	Translating Pharmacogenomic Research to Therapeutic Potentials. , 2019, , 103-122.		0

#	Article	IF	Citations
38	Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 449-458.	1.5	7
39	Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions. Genetics in Medicine, 2019, 21, 1345-1354.	1.1	68
40	Population-scale genomicsâ€"Enabling precision public health. Advances in Genetics, 2019, 103, 119-161.	0.8	9
41	Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genetics in Medicine, 2019, 21, 1224-1232.	1.1	57
42	Challenges and Solutions for Integrating and Financing Personalized Medicine in Healthcare Systems: A Systematic Literature Review. Journal of Risk and Financial Management, 2020, 13, 283.	1.1	3
43	The landscape of pharmacogenetic testing in a US managed care population. Genetics in Medicine, 2020, 22, 1247-1253.	1.1	27
44	Other side of the coin for personalised medicine and healthcare: content analysis of â€˜personalisedâ€™ practices in the literature. BMJ Open, 2016, 6, e010243.	0.8	26
45	How Much Evidence is Necessary for Pharmacogenomic Testing Implementation?. Clinical & Experimental Pharmacology, 2012, 02, .	0.3	3
46	Pharmacogenetic testing among patients with depression in a US managed care population. Clinical and Translational Science, 2022, 15, 1644-1653.	1.5	2
47	Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options. Applied Health Economics and Health Policy, 2022, 20, 501-524.	1.0	19
48	Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country.. Iranian Journal of Pharmaceutical Research, 2021, 20, 92-106.	0.3	1
49	Genetic Testing and/or Counseling for Colorectal Cancer by Health Insurance Type. Journal of Personalized Medicine, 2022, 12, 1146.	1.1	3
50	Association between Health Insurance Type and Genetic Testing and/or Counseling for Breast and Ovarian Cancer. Journal of Personalized Medicine, 2022, 12, 1263.	1.1	2